source
- Replimune appoints former Genentech exec Michelle DiNapoli as chief commercial officer after accelerated melanoma approvalReplimune announced that Michelle DiNapoli will become its chief commercial officer, starting August 18. DiNapoli previously held senior roles at Genentech, where she led commercial operations. Th…
- Ambros Therapeutics merges with Werewolf, raises $150M to fund phase 3 trial of rare disease drugAmbros Therapeutics announced an all‑stock reverse merger with Werewolf Therapeutics, accompanied by a $150 million private placement. The transaction will see the combined company operate under th…